Journal of Medicinal Chemistry · 2021 · 18 citations · 21 references
MedicineMedicinal ChemistryPharmacologyCell SignalingMolecular PharmacologySignal TransductionAllosteric ModulationAllosteric RegulationDiabetes MellitusG Protein-coupled Receptor SignalingGlucagon-like Peptide-1 Receptor AgonistsGlycemic ControlAgonist ActivityAllosteric Modulation Of G Protein-coupled ReceptorsG Protein-coupled SignalingG-protein-coupled ReceptorsGlucagon-like Peptide 1 Receptor AgonismGlucose-dependent Insulin SecretionGlucose-stimulated Insulin SecretionPositive Allosteric Modulation
The identification of LSN3318839, a positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), is described. LSN3318839 increases the potency and efficacy of the weak metabolite GLP-1(9-36)NH2 to become a full agonist at the GLP-1R and modestly potentiates the activity of the highly potent full-length ligand, GLP-1(7-36)NH2. LSN3318839 preferentially enhances G protein-coupled signaling by the GLP-1R over β-arrestin recruitment. Ex vivo experiments show that the combination of GLP-1(9-36)NH2 and LSN3318839 produces glucose-dependent insulin secretion similar to that of GLP-1(7-36)NH2. Under nutrient-stimulated conditions that release GLP-1, LSN3318839 demonstrates robust glucose lowering in animal models alone or in treatment combination with sitagliptin. From a therapeutic perspective, the biological properties of LSN3318839 support the concept that GLP-1R potentiation is sufficient for reducing hyperglycemia.
21
Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, M Gabe et al. · JCI Insight · 2020 · 487 citations · Full text